Strategic Account Executive, Diagnostics (California)
Thermo Fisher ScientificFull Time
Junior (1 to 2 years)
Candidates should possess a Bachelor's degree in life science, biology, business, or marketing, with an MBA preferred. A minimum of 3 years of direct account management experience in molecular diagnostics, ideally with a focus on MRD testing, is required. Proven revenue generation in diagnostics, pharmaceuticals, or biotechnology, along with experience with major cancer centers and oncology practices, is essential. The role demands comfort engaging with executive-level stakeholders, an in-depth understanding of the oncology diagnostics payer and reimbursement environment, and proficiency in Microsoft Office and Salesforce.com. Strong independent work ethic, communication, project management, prioritization, and cross-functional relationship-building skills are necessary, as are advanced presentation skills and business acumen.
The MRD Clinical Account Executive will drive the adoption of Tempus's MRD testing services within North Florida, focusing on major cancer centers, health systems, and community practices. This includes engaging with Key Opinion Leaders and clinicians to establish and expand business opportunities, developing strategic plans for client acquisition and retention, and implementing laboratory services agreements. The role involves collaborating with internal sales teams, identifying and developing partnership opportunities, providing market feedback to leadership, and developing a comprehensive business plan for the territory. The executive will also represent Tempus's company culture with integrity, respect, and trust.
AI-driven healthcare data analysis platform
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.